Tag: infectious disease therapeutics market share

Uncover key drivers, emerging technologies, and competitive movements shaping the infectious disease therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Infectious Disease Therapeutics Market in 2030?

The infectious disease therapeutics market size has seen significant growth in recent years. This market is projected to expand from $150.6 billion in 2025 to $160.84 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.8%. Historically, this growth was fueled by the substantial global prevalence of infectious diseases, the broad application of antibiotics and antivirals, government-led immunization initiatives, an expansion in pharmaceutical manufacturing capabilities, and enhanced investment in infectious disease research.

The infectious disease therapeutics market size is projected to experience robust expansion over the coming years. This market is anticipated to reach $200.87 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.7%. Factors driving this growth during the projection period include escalating antimicrobial resistance rates, a greater occurrence of infectious disease outbreaks, wider global vaccination coverage, an expanding need for new antiviral treatments, and enhanced public health readiness programs. Key trends for the forecast duration encompass a heightened emphasis on managing antimicrobial resistance, the accelerating creation of broad-spectrum treatments, the increasing use of combined drug therapies, the broadening of rapid-response treatments for outbreaks, and augmented funding for vaccine development and reserves.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15594&type=smp

What Drivers Are Influencing Production Trends In The Infectious Disease Therapeutics Market?

The anticipated increase in infectious disease prevalence is projected to fuel the expansion of the infectious disease therapeutics market in the future. These diseases are ailments triggered by pathogenic agents including bacteria, viruses, fungi, parasites, or prions. The surge in infectious diseases stems from several critical factors, such as shifts in climate and environmental disturbances, antimicrobial resistance, compromised immune systems, greater human-animal interaction, and ecological imbalances. Therapeutics for infectious diseases are crucial for managing infections, lowering illness and death rates, and curbing the dissemination of transmissible diseases within local areas and across wider populations. For example, data from October 2023, provided by the National Health Service (NHS) England, a UK government body, indicated that in 2022/23, hospitals recorded 147,285 primary admissions for urinary tract infections (UTI). Individuals over 65 years old accounted for 56% of these incidents, totaling 82,392 hospitalizations. The 80–84 age bracket experienced the most admissions, with 17,280 instances. Consequently, the growing incidence of infectious diseases acts as a catalyst for the infectious disease therapeutics market.

Which Segment Groups Are Influencing The Infectious Disease Therapeutics Market?

The infectious disease therapeutics market covered in this report is segmented –

1) By Type: Drugs, Vaccines

2) By Disease: Tuberculosis, HIV/AIDS, Influenza, Hepatitis, Other Diseases

3) By End-User: Hospitals And Clinics, Retail Pharmacies, Research Organizations, Other End Users

Subsegments:

1) By Drugs: Antibiotics, Antivirals, Antifungals, Antiparasitics, Other Therapeutic Drugs (Monoclonal Antibodies, Immunomodulators)

2) By Vaccines: Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines, Mrna Vaccines, Dna Vaccines, Toxoid Vaccines

What Trends Are Driving The Growth Trajectory Of The Infectious Disease Therapeutics Market?

Major companies operating in the infectious disease therapeutics market are prioritizing the integration of multispecific antibody platforms, such as the multispecific therapeutic antibody reactor (MSTAR), to elevate efficacy, broaden protection, and strengthen responsiveness against emerging viral threats. The multispecific therapeutic antibody reactor (MSTAR) represents an advanced multispecific antibody technology that combines multiple independent binding regions into a single therapeutic molecule, thereby enabling features like broad viral neutralization, simultaneous targeting of various epitopes, and swift adaptation to new variants. For instance, in September 2023, ModeX Therapeutics Inc, a US-based clinical stage biopharmaceutical company, obtained a contract from the Biomedical Advanced Research and Development Authority to further develop its multispecific antibody candidates. These candidates are designed for the treatment and prevention of viral infectious diseases including COVID 19 and influenza, characterized by broad activity against circulating viral strains, potential compatibility with gene-based delivery using mRNA or DNA vectors, and a multi-binding site architecture. This multispecific antibody approach enhances therapeutic outcomes by shortening development timelines, expanding protective coverage, and reducing the intricacy associated with combination biologic treatments.

Who Are The Primary Competitors In The Global Infectious Disease Therapeutics Market?

Major companies operating in the infectious disease therapeutics market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, AstraZeneca, Novartis International AG, GlaxoSmithKline plc, Gilead Sciences Inc., Janssen Pharmaceuticals, Moderna Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim GmbH, BioCryst Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/infectious-disease-therapeutics-global-market-report

Which Regions Are Poised For Strategic Growth In The Infectious Disease Therapeutics Market?

North America was the largest region in the infectious disease therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Infectious Disease Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15594&type=smp

Browse Through More Reports Similar to the Global Infectious Disease Therapeutics Market 2026, By The Business Research Company

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Anti Infective Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Will The Infectious Disease Therapeutics Market Valuation Change Between Now And 2029?

In the last few years, the market size for infectious disease therapeutics has seen substantial growth. The market is projected to expand from 2024’s $141.08 billion to $150.6 billion in 2025, with a compound annual growth rate (CAGR) of 6.7%. The surge in growth during this period is attributed to various factors such as increased instances of infectious diseases, growing occurrence of viral diseases, more awareness about diagnostic procedures, escalating demand for efficient and timely diagnostic testing, burgeoning requirement for cost-effective generic medications, a rising prevalence of infectious diseases, and the escalating significance of antimicrobial stewardship.

In the coming years, the market size of therapeutics for infectious diseases is poised to witness significant growth, escalating to $191.97 billion by 2029, with a compound annual growth rate (CAGR) of 6.3%. The progression in the forecast period can be ascribed to factors such as increased investments, augmentation of clinical trial studies, the rising number of clinical trials, heightened attention towards preventing infectious diseases, and growing cognizance for early diagnosis. The forecast period will also see dominant trends such as collaborations, product approvals, investments, and research and development in the therapeutics arena.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15594&type=smp

What Underlying Factors Are Supporting The Infectious Disease Therapeutics Market Growth?

An increase in the occurrence of infectious diseases is projected to boost the infectious disease therapeutics market. Pathogenic organisms like bacteria, fungi, viruses, prions, or parasites are responsible for these diseases. Multiple elements such as ecological disruption, increasing interactions with animals, climate change, antimicrobial resistance, and weakened immune systems contribute to the rise of these diseases. Therapies for these diseases perform a crucial function in managing these infections, lessening morbidity and mortality, and halting the transmission of these diseases amongst communities and across populations. The Centers for Disease Control and Prevention, a government agency from the US, revealed in November 2023 that there were 8,331 tuberculosis (TB) cases in 2022 in the United States, representing an incidence rate of 2.5 per 100,000 people. The number of cases rose by 5.9% and the incident rate saw a 5.5% boost compared to figures from 2021. Consequently, escalating occurrences of infectious diseases steer the growth of the infectious disease therapeutics market.

Which Sub-Segments Are Driving Growth Within The Infectious Disease Therapeutics Market?

The infectious disease therapeuticsmarket covered in this report is segmented –

1) By Type: Drugs; Vaccines

2) By Disease: Tuberculosis; HIV/AIDS; Influenza; Hepatitis; Other Diseases

3) By End-User: Hospitals And Clinics; Retail Pharmacies; Research Organizations; Other End Users

Subsegments:

1) By Drugs – Antibiotics; Antivirals; Antifungals; Antiparasitics; Other Therapeutic Drugs (Monoclonal Antibodies, Immunomodulators)

2) By Vaccines – Inactivated Vaccines; Live Attenuated Vaccines; Subunit Vaccines; Mrna Vaccines; Dna Vaccines; Toxoid Vaccines

What Key Trends Are Driving Growth In The Infectious Disease Therapeutics Market?

Major firms in the infectious disease therapeutics market are putting money into infectious disease drugs with goals to innovate more effective therapies, battle antimicrobial resistance, broaden their product offerings, and respond to emerging infectious hazards. These investments are targeted towards enhancing patient results, fulfilling unfulfilled medical necessities, and aiding international public health initiatives in the control and management of infectious diseases. For example, in June 2022, the UK’s GSK healthcare company committed £1 billion ($1.09 billion) to proactively tackle infectious diseases prevalent in less affluent countries. This move is designed to boost research and development in order to address diseases that have a greater impact on these areas. The significant gap in health research funding and resources between wealthy and low- to middle-income countries highlights the pressing need for such forward-thinking investments to boost population health equally.

Which Companies Hold A Competitive Edge In The 991 Market?

Major companies operating in the infectious disease therapeutics market are Pfizer Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, Thermo Fisher Scientific, AstraZeneca, Abbott Laboratories, Novartis International AG, Danaher Corporation, GlaxoSmithKline plc, Gilead Sciences Inc., Janssen Pharmaceutical, Siemens Healthineers, Moderna Inc., Becton, Dickinson, and Company, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim GmbH, BioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories, Qiagen N.V., Ortho Clinical Diagnostics, BioCryst Pharmaceuticals Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/infectious-disease-therapeutics-global-market-report

Which Region Dominates The Infectious Disease Therapeutics Market Today?

North America was the largest region in the infectious disease therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=15594&type=smp

Browse Through More Reports Similar to the Global Infectious Disease Therapeutics Market 2025, By The Business Research Company

Veterinary Infectious Disease Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/veterinary-infectious-disease-diagnostics-global-market-report

Veterinary Anti Infectives Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/veterinary-anti-infectives-global-market-report

Infection Prevention Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/infection-prevention-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Infectious Disease Therapeutics Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The infectious disease therapeutics market size has demonstrated robust growth in recent years. It is projected to expand from $141.08 billion in 2024 to $150.6 billion in 2025, showing a compound annual growth rate (CAGR) of 6.7%. The historical increase can be attributed to several factors including the rising prevalence of infectious diseases, the increasing incidence of viral diseases, greater awareness about diagnosis, a rising demand for efficient and quick diagnostic testing, a growing demand for cost-effective generic drugs, the growing prevalence of infectious diseases, and the growing importance of antimicrobial stewardship.

The infectious disease therapeutics market size is anticipated to undergo significant expansion in the coming years. It is projected to reach “$191.97 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.3%. This growth during the forecast period is primarily driven by factors such as increasing investments, the broadening of clinical trial studies, a rise in the number of clinical trials, a greater emphasis on infectious disease prevention, heightened awareness regarding early diagnosis, and increasing overall awareness and funding. Major developments expected in the forecast period include strategic partnerships, product approvals, continued investments, and advancements in research and development within therapeutics.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15594&type=smp

What Are The Key Drivers Of Growth In The Infectious Disease Therapeutics Market?

The increasing occurrence of infectious diseases is projected to drive the expansion of the infectious disease therapeutics market in the coming period. Such diseases represent ailments brought on by disease-causing microorganisms like bacteria, viruses, fungi, parasites, or prions. The escalation in infectious diseases stems from various principal factors including climate shifts and environmental disturbances, resistance to antimicrobials, compromised immune systems, greater contact with animals, and ecological imbalances. Infectious disease therapeutics are crucial for addressing infections, diminishing sickness and fatalities, and managing the dissemination of transmissible conditions within and across populations. For example, in November 2023, as per the Centers for Disease Control and Prevention, a US-based government agency, the United States registered 8,331 tuberculosis (TB) cases in 2022, displaying an incidence rate of 2.5 per 100,000 people. This represents a 5.9% increase in case numbers and a 5.5% rise in the incidence rate compared to 2021. Consequently, the growing prevalence of infectious diseases acts as a driver for the infectious disease therapeutics market.

How Is The Infectious Disease Therapeutics Market Classified Into Different Segments?

The infectious disease therapeuticsmarket covered in this report is segmented –

1) By Type: Drugs; Vaccines

2) By Disease: Tuberculosis; HIV/AIDS; Influenza; Hepatitis; Other Diseases

3) By End-User: Hospitals And Clinics; Retail Pharmacies; Research Organizations; Other End Users

Subsegments:

1) By Drugs – Antibiotics; Antivirals; Antifungals; Antiparasitics; Other Therapeutic Drugs (Monoclonal Antibodies, Immunomodulators)

2) By Vaccines – Inactivated Vaccines; Live Attenuated Vaccines; Subunit Vaccines; Mrna Vaccines; Dna Vaccines; Toxoid Vaccines

How Are Emerging Market Trends Shaping The Infectious Disease Therapeutics Industry Landscape?

Major companies operating in the infectious disease therapeutics market are channeling investments into infectious disease drugs to develop superior treatments, effectively combat antimicrobial resistance, broaden their product portfolios, and address novel infectious threats. These financial undertakings are intended to enhance patient outcomes, meet existing unmet medical needs, and support global public health efforts aimed at controlling and managing infectious diseases. For instance, in June 2022, GSK, a UK-based healthcare company, invested £1 billion ($1.09 billion) to proactively tackle infectious diseases prevalent in lower-income countries. This specific initiative seeks to bolster research and development endeavors focused on combating diseases that disproportionately affect these regions. The notable disparity in health research funding and resources between high-income nations and low- and middle-income countries highlights the critical urgency for such forward-thinking investments to equitably improve population health.

Which Leading Players Are Enhancing Their Infectious Disease Therapeutics Market Presence Worldwide?

Major companies operating in the infectious disease therapeutics market are Pfizer Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, Thermo Fisher Scientific, AstraZeneca, Abbott Laboratories, Novartis International AG, Danaher Corporation, GlaxoSmithKline plc, Gilead Sciences Inc., Janssen Pharmaceutical, Siemens Healthineers, Moderna Inc., Becton, Dickinson, and Company, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim GmbH, BioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories, Qiagen N.V., Ortho Clinical Diagnostics, BioCryst Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/infectious-disease-therapeutics-global-market-report

Which Regional Markets Are Contributing Most To The Infectious Disease Therapeutics Industry Expansion?

North America was the largest region in the infectious disease therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Infectious Disease Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=15594&type=smp

Browse Through More Reports Similar to the Global Infectious Disease Therapeutics Market 2025, By The Business Research Company

Veterinary Infectious Disease Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/veterinary-infectious-disease-diagnostics-global-market-report

Veterinary Anti Infectives Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/veterinary-anti-infectives-global-market-report

Infection Prevention Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/infection-prevention-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Infectious Disease Therapeutics Market Growth Evolved From 2024 To 2025, And What’s Ahead?

In the past few years, the infectious disease therapeutics market has experienced substantial expansion. Its size is projected to increase from $141.08 billion in 2024 to $150.6 billion in 2025, representing a compound annual growth rate (CAGR) of 6.7%. Factors contributing to this growth during the historic period include increased instances of infectious diseases, a rise in viral diseases, growing awareness about diagnostic measures, an increased need for swift and efficient diagnostic tests, and escalating demand for economical generic medications. Other factors, such as the burgeoning prevalence of infectious diseases and the rising significance of antimicrobial stewardship, also play key roles in this growth.

The market size of therapeutics for infectious diseases is projected to experience robust growth in the coming years, increasing to$191.97 billion in 2029″ with a compound annual growth rate (CAGR) of 6.3%. This anticipated growth throughout the forecast period can be credited to an influx of investments, the broadening scope of clinical trial studies, a rising number of these trials, a heightened emphasis on preventing infectious diseases, an increased alertness towards early diagnosis, and growing education and funding. Key trends for the forecast period encompass partnerships, product approvals, investments, and therapeutic research and developments.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15594&type=smp

What are the Fundamental Drivers and Innovations Shaping the Infectious Disease Therapeutics Market?

The surging occurrence of infectious diseases is forecasted to fuel the expansion of the infectious disease therapeutics market in the future. These diseases are the result of harmful microorganisms including bacteria, viruses, fungi, parasites, or prions. Several contributing factors like environmental disruption and climate change, antimicrobial resistance, weakened immune responses, increased interactions with animals and ecological disturbances have led to an increase in such infectious diseases. The imperative role that infectious disease therapeutics play includes treating these infections, reducing the incidence of sickness and death, and managing the dissemination of communicable diseases within communities and across entire populations. To illustrate, the Centers for Disease Control and Prevention, a government agency based in the US, reported that in 2022, there were 8,331 tuberculosis (TB) cases recorded in the United States with an incidence rate of 2.5 per 100,000 people. This signified a 5.9% surge in the case numbers and a 5.5% rise in the incidence rate compared to 2021. Thus, the increasing occurrence of infectious diseases propels the infectious disease therapeutics market.

How Is the Infectious Disease Therapeutics Market Segmented?

The infectious disease therapeuticsmarket covered in this report is segmented –

1) By Type: Drugs; Vaccines

2) By Disease: Tuberculosis; HIV/AIDS; Influenza; Hepatitis; Other Diseases

3) By End-User: Hospitals And Clinics; Retail Pharmacies; Research Organizations; Other End Users

Subsegments:

1) By Drugs – Antibiotics; Antivirals; Antifungals; Antiparasitics; Other Therapeutic Drugs (Monoclonal Antibodies, Immunomodulators)

2) By Vaccines – Inactivated Vaccines; Live Attenuated Vaccines; Subunit Vaccines; Mrna Vaccines; Dna Vaccines; Toxoid Vaccines

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=15594&type=smp

Which Regions Are Driving the Next Phase of the Infectious Disease Therapeutics Market Growth?

North America was the largest region in the infectious disease therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the Infectious Disease Therapeutics Market?

Major firms active in the infectious disease therapeutics market are channeling funds into infectious disease drugs with the objectives of devising stronger treatments, curbing antimicrobial resistance, broadening their product ranges, and combatting emerging infectious threats. They aim through these investments to better meet patient needs, address gaps in medical treatment, and support global public health endeavors in controlling and managing infectious diseases. For instance, GSK, a healthcare company originating from the UK, dedicated £1 billion ($1.09 billion) in June 2022 towards addressing infectious diseases prevalent in less affluent countries. The goal of this project is to heighten research and development efforts against diseases that disproportionally impact these areas. The lack of balance in health research funding between affluent and low to middle-income countries highlights the crucial need for such preventive investments to promote health equality.

View the full report here:

https://www.thebusinessresearchcompany.com/report/infectious-disease-therapeutics-global-market-report

How Is the Infectious Disease Therapeutics Market Defined and What Are Its Core Parameters?

Infectious disease therapeutics refers to the various treatments and interventions aimed at combating illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, and parasites. The goal of infectious disease therapeutics is to either eliminate the infectious agent from the body or to control its replication and spread, thereby alleviating symptoms, preventing complications, and ultimately promoting recovery.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15594

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Infectious Disease Therapeutics Market Expected to Grow Between 2025 And 2029?

The market size of therapeutics for infectious diseases has experienced significant growth in the past few years. The market, which will increase from $141.08 billion in 2024 to $151.04 billion in 2025, is projected to have a compound annual growth rate (CAGR) of 7.1%. The expansion during the historical period can be credited to various factors such as increased occurrence of infectious diseases, a rise in viral disease cases, heightened awareness regarding diagnosis, escalating demand for rapid and effective diagnostic tests, increased demand for affordable generic drugs, a growing incidence of infectious diseases, and an elevated significance of antimicrobial stewardship.

What Growth Rate Is Anticipated for the Infectious Disease Therapeutics Market in the Coming Years?

The market for therapeutic treatments related to infectious diseases is projected to see a robust surge in the coming years, escalating to reach $196.5 billion by 2029 with a CAGR of 6.8%. This looming growth in the forecasted timeline can be credited to a rise in investments, a broader scope of clinical trial studies, an upturn in the number of clinical trials, a heightened emphasis on preventing infectious diseases, growing consciousness about early diagnosis and an increase in awareness and funding. The key trends anticipated during the forecasted period entail partnerships, product endorsements, advancements in investment and research in therapeutics.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15594&type=smp

Who Are the Leading Companies in the Infectious Disease Therapeutics Market?

Major companies operating in the infectious disease therapeutics market are Pfizer Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, Thermo Fisher Scientific, AstraZeneca, Abbott Laboratories, Novartis International AG, Danaher Corporation, GlaxoSmithKline plc, Gilead Sciences Inc., Janssen Pharmaceutical, Siemens Healthineers, Moderna Inc., Becton, Dickinson, and Company, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim GmbH, BioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories, Qiagen N.V., Ortho Clinical Diagnostics, BioCryst Pharmaceuticals Inc.

What Are the Key Drivers of the Infectious Disease Therapeutics Market?

Expectations for the infectious disease therapeutics market’s expansion are being fueled by the increasing prevalence of infectious diseases. Such diseases, brought on by pathogens like bacteria, viruses, fungi, parasites, or prions, are on the rise due to numerous key elements including climate shifts, environmental upheaval, antimicrobial resistance, compromised immune systems, more interactions with animals, and ecological imbalances. Therapies for infectious diseases are critical in managing infections, reducing cases and deaths, and limiting the transmission of easily spread diseases within and between populations. As an example, the US-based Centers for Disease Control and Prevention reported in November 2023 that the United States saw 8,331 tuberculosis (TB) cases in 2022, which corresponds to an incidence rate of 2.5 per 100,000 people. This represents a 5.9% rise in cases and a 5.5% jump in the incidence rate compared to 2021. Consequently, this increasing prevalence of infectious diseases is fueling the growth of the infectious disease therapeutics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15594&type=smp

What Are the Key Market Segments in the Infectious Disease Therapeutics Industry?

The infectious disease therapeutics market covered in this report is segmented –

1) By Type: Drugs, Vaccines

2) By Disease: Tuberculosis, HIV/AIDS, Influenza, Hepatitis, Other Diseases

3) By End-User: Hospitals And Clinics, Retail Pharmacies, Research Organizations, Other End Users

Subsegments:

1) By Drugs – Antibiotics, Antivirals, Antifungals, Antiparasitics, Other Therapeutic Drugs (Monoclonal Antibodies, Immunomodulators)

2) By Vaccines – Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines, Mrna Vaccines, Dna Vaccines, Toxoid Vaccines

What Are the Latest Trends in the Infectious Disease Therapeutics Market?

Leading corporations in the infectious disease therapeutics market are channeling resources into the development of drugs for infectious diseases. Their goals are to produce more effective treatments, fight antimicrobial resistance, broaden their range of products, and tackle new threats from infectious diseases. These investment strategies are designed to enhance patient outcomes, fulfill unfulfilled healthcare prerequisites, and lend support to global public health drives targeted at controlling and treating infectious diseases. Take for example, GSK, a healthcare firm from the UK, which in June 2022, allocated £1 billion ($1.09 billion) to proactively tackle infectious diseases in less affluent nations. The objective of this plan is to accelerate research and development activities to fight diseases that disproportionately affect these areas. The unequal distribution of funding and resources for health research between affluent and low- to middle-income countries emphasizes the pressing need for such anticipatory investments to fairly enhance population health.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/infectious-disease-therapeutics-global-market-report

What Are the Key Regional Markets in the Infectious Disease Therapeutics Industry?

North America was the largest region in the infectious disease therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15594

This Report Delivers Insight On:

1. How big is the infectious disease therapeutics market, and how is it changing globally?

2. Who are the major companies in the infectious disease therapeutics market, and how are they performing?

3. What are the key opportunities and risks in the infectious disease therapeutics market right now?

4. Which products or customer segments are growing the most in the infectious disease therapeutics market?

5. What factors are helping or slowing down the growth of the infectious disease therapeutics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model